---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-077804"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2022-03-17T23:59:59+00:00"
generated_at: "2026-06-26T22:04:35.270045+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cullinan Oncology reports Q4 2021 net loss of $34.4M; cash $430.9M through 2024

## Summary
- Net loss $34.4M in Q4 2021 vs $18.4M in Q3 2021; FY 2021 net loss $67.5M vs $59.5M in FY 2020.
- Cash and investments $430.9M as of Dec 31, 2021, expected to fund operations through 2024.
- CLN-081 Phase 1/2a data: 39% confirmed PR at 100mg BID; median DOR >15 months, PFS 12 months.
- CLN-081 received FDA Breakthrough Therapy Designation in Jan 2022; regulatory update expected Q1 2022.
- CLN-049 and CLN-619 first-in-human dosing initiated Dec 2021; initial data expected by mid-2023.

## SEC filing metadata
- accession: 0001193125-22-077804
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2022-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312522077804/0001193125-22-077804-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312522077804/d331653d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-077804
- JSON: https://secwatch.observer/filing/0001193125-22-077804.json
- Plain text: https://secwatch.observer/filing/0001193125-22-077804.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.